TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Purpose: TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion-positive cancers and consequently are now an established standard of care. Little is known, however, about the demographics, outcomes, response to alternative standard therapies, or genomic characteristics of TRK fusion-positive cancers. Experimental Design: Utilizing a center-wide screening program involving more than…
